{"id":"NCT02231749","sponsor":"Bristol-Myers Squibb","briefTitle":"Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)","officialTitle":"A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-16","primaryCompletion":"2017-06-26","completion":"2025-03-21","firstPosted":"2014-09-04","resultsPosted":"2018-10-16","lastUpdate":"2025-06-26"},"enrollment":1390,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558","Opdivo"]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["Yervoy"]},{"type":"DRUG","name":"Sunitinib","otherNames":["Sutent"]}],"arms":[{"label":"Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg","type":"EXPERIMENTAL"},{"label":"Arm B: Sunitinib 50 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.","primaryOutcome":{"measure":"Investigator-assessed Objective Response Rate(ORR) in Intermediate/Poor Risk Participants Per IRRC Using RECIST v1.1","timeFrame":"From first dose until date of documented disease progression or subsequent therapy, whichever occurs first (assessed up to June 2017, approximately 31 months)","effectByArm":[{"arm":"Nivolumab + Ipilimumab","deltaMin":41.6,"sd":null},{"arm":"Sunitinib","deltaMin":26.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":189,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","Finland","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Poland","South Korea","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39060019","38280218","37146227","36549781","35383908","35383907","34750035","33246931","32661118","31992108","31633185","31427204","30658932","29562145"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":305,"n":547},"commonTop":["Fatigue","Diarrhoea","Nausea","Hypertension","Decreased appetite"]}}